REVIEW PAPER
Macrophage activation syndrome
Submission date: 2013-07-06
Final revision date: 2013-09-02
Acceptance date: 2013-11-18
Online publication date: 2013-12-24
Publication date: 2013-12-20
Reumatologia 2013;51(6):459-466
KEYWORDS
TOPICS
Cytokines, Inflammatory mediators and adaptive immunity in rheumatic diseasesRheumatoid arthritis- aetiology, pathogenesis, clinical features and treatmentInfection related rheumatoid diseases
ABSTRACT
Macrophage activation syndrome (MAS) is a severe complication of systemic connective tissue diseases, particularly systemic juvenile idiopathic arthritis, systemic lupus erythematosus and adult-onset Still’s disease. It is a life-threatening disorder arising from immunoregulation inherited or acquired dysfunction of the NK cells and cytotoxic T-lymphocytes. It is characterized by multi-organ failure with a number of clinical symptoms. So far, there is no standard procedure for treatment. Glucocorticoids, intravenous immunoglobulin, sometimes cyclosporine A and etoposide are used.
REFERENCES (28)
1.
Kelly A, Ramanan AV. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol 2007; 19: 477-481.
2.
Henter J-I. HLH-2004 protocol [Internet]. Histiocyte Society; 2004. Available from: www.histio.org/society/protocols.
3.
Klaudel-Dreszler M, Rutynowska-Pronicka O, Gietka P i wsp. Propozycja standardu diagnostyczno-terapeutycznego dla dzieci z podejrzeniem pierwotnego lub wtórnego zespołu hemofagocytarnego w oparciu o doświadczenia Instytutu „Pomnik – Centrum Zdrowia Dziecka” w Warszawie. Standardy medyczne. Pediatria 2010; 7: 194-205.
4.
Zoń-Giebel A, Giebel S. Zespół aktywacji makrofagów – reaktywna postać limfohistiocytozy hemofagocytarnej. Reumatologia 2008; 46: 21-26.
5.
Ravelli A, Grom AA, Behrens EM, et al. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012; 13: 289-298.
6.
Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program 2009: 127-131.
7.
Machaczka M. Hemophagocytic lymphohistiocytosis – a contemporary medical problem. Pol Merkur Lek 2012; 32: 59-63.
8.
Larroche C. Hemophagocytic lymphohistiocytosis in adults: diagnosis and treatment. Joint Bone Spine 2012; 79: 356-361.
9.
Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH. Br J Haematol 2013; 161: 609-622.
10.
Maakaroun NR, Moanna A, Jacob JT, et al. Viral infections associated with haemophagocytic syndrome. Rev Med Virol 2010; 20: 93-105.
11.
Jayakar BA, Hashkes PJ. Macrophage activation syndrome: why and what should a gastroenterologist know. J Clin Gastroenterol 2011; 45: 210-214.
12.
Deane S, Selmi C, Teuber SS, et al. Macrophage activation syndrome in autoimmune disease. Int Arch Allergy Immunol 2010; 153: 109-120.
13.
Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood 2011; 118: 4041-4052.
14.
Lin C-I, Yu H-H, Lee J-H, et al. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clin Rheumatol 2012; 31: 1223-1230.
15.
Pringe A, Trail L, Ruperto N, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? Lupus 2007; 16: 587-592.
16.
Parodi A, Davì S, Pringe AB, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum 2009; 60: 3388-3399.
17.
Tristano AG. Macrophage activation syndrome: a frequent but under-diagnosed complication associated with rheumatic diseases. Med Sci Monit 2008; 14: RA27-RA36.
18.
Vilaiyuk S, Sirachainan N, Wanitkun S, et al. Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review. Clin Rheumatol 2013; 32: 899-904.
19.
Jędrzejczak WW. Limfohistiocytoza hemofagocytarna – rzadko rozpoznawany uleczalny stan bezpośredniego zagrozenia zycia występujący równiez u dorosłych. Acta Haematol Polonica 2008; 39: 515-526.
20.
Gietka P, Wieteska-Klimczak A, Smorczewska-Kiljan A i wsp. Reaktywne zespoły hemofagocytarne u dzieci z chorobami reumatycznymi. Reumatologia 2011; 49: 96-107.
21.
Gupta AA, Tyrrell P, Valani R, et al. Experience with hemophagocytic lymphohistiocytosis/macrophage activation syndrome at a single institution. J Pediatr Hematol Oncol 2009; 31: 81-84.
22.
Lehmberg K, Pink I, Eulenburg C, et al. Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis. J Pediatr 2013; 162: 1245-1251.
23.
Bennett TD, Fluchel M, Hersh AO, et al. Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis. Arthritis Rheum 2012; 64: 4135-4142.
25.
Bustos B R, Carrasco A C, Toledo R C. Plasmapheresis for macrophage activation syndrome and multiorgan failure as first presentation of juvenile dermatomyositis. Ann Pediatr (Barc) 2012; 77: 47-50.
26.
Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 2008; 4: 615-620.
27.
Loh NK, Lucas M, Fernandez S, et al. Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra. Intern Med J 2012; 42: 1358-1362.
28.
De Boysson H, Février J, Nicolle A, et al. Tocilizumab in the treatment of the adult-onset Still’s disease: current clinical evidence. Clin Rheumatol 2013; 32: 141-147.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
